Above: A small packaging line in process at Metrics includes filling, desiccant, capping & torquing, induction sealing, labeling and cartoning.
Left: Metrics’ hard wall isolation units used for potent product development and manufacturing, with different equipment installed.
New technologies, equipment, and partner make Metrics a global CDMO
To keep up with market demands and customer expectations, CDMOs are constantly looking at new technologies, equipment and partners to increase their value and position. When all three
come together and allow a company to better serve its cli-
ents and expand market reach and capabilities, you have
what most would consider a
Metrics Inc., a contract
and manufacturing company
of oral solid dosage pharmaceuticals, has a reputation
as one of the leading Phase
I-III clinical trial materials
manufacturers in the United
States. Recently, the company
was bought through a strategic corporate purchase by
Australia’s Mayne Pharma.
This has given it access to global markets and additional
oral solid dosage technologies.
HISTORY AND TECHNOLOGIES
Metrics, based in Greenville, N.C., was founded as a contract analytical laboratory in 1994 by current president and
former Burroughs Wellcome scientist Phil Hodges and ECU
professor Dr. John Bray. As often happens in this industry,
the acquisition of one company by another created a glut of
experienced pharmaceutical professionals and Metrics took
advantage of this. Six months after the formation of Metrics,
Glaxo acquired Burroughs Wellcome. This situation enabled
Metrics to secure highly experienced people in a short time
and expand its services to include the manufacture of Phase
I clinical trial materials. In 1998, Metrics started providing
small-scale manufacturing and product development.
By 2000, Metrics had grown to 55 employees, prompting it
to build a 44,000-square-foot facility.
“From 2000 to 2006, our growth was focused on build-
ing formulation development relationships for Phase 1 and
A Potent Combination
■ By Mike Auerbach, Editor in Chief
■ 8 NOV/DEC 2013 | PHARMACEUTICAL PROCESSING
■ PHARMPRO. COM
AND PHASE I – III CLINICAL
• Powder and bead-filled capsules
• Immediate release
• Sustained release
• Matrix tablets
• Coated tablets
• Coated beads
• Liquid-filled hard gels